Interleukin-3 is a predictive marker for severity and outcome during SARS-CoV-2 infections
A. Benard, A. Jacobsen, M. Brunner, C. Krautz, B. Klosch, I. Swierzy, E. Naschberger, T. Birkholz, I. Castellanos, D. Trufa, H. Sirbu, M. Vetter, A. E. Kremer, K. Hildner, A. Hecker, F. Edinger, M. Tenbusch, E. Richter, H. Streeck, M. M. Berger, T. Brenner, M. A. Weigand, F. K. Swirski, G. Schett, R. Grutzmann, G. F. Weber
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a worldwide health threat. Here, we report that low plasma interleukin-3 (IL-3) levels were associated with increased severity and mortality during SARS-CoV-2 infections. IL-3 promoted the recruitment of antiviral circulating plasmacytoid dendritic cells (pDCs) into the airways by stimulating CXCL12 secretion from pulmonary CD123+ epithelial cells. This study identifies IL-3 as a predictive disease marker and potential therapeutic target for SARS-CoV-2 infections.Competing Interest StatementThe authors have declared no competing interest.View Full Text
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- The IL-33/ST2 signaling axis drives pathogenesis in acute SARS-CoV-2 infection
Claire Fleming, Henry J. McSorley, … William A. Petri·bioRxiv·Nov 27, 2024
- IL-13 decreases susceptibility to airway epithelial SARS-CoV-2 infection but increases disease severity in vivo
Shreya Ghimire, Biyun Xue, … Alejandro A. Pezzulo·EBioMedicinePeer-reviewed·Sep 17, 2025
- Distinct SARS-CoV-2 sensing pathways in pDCs driving TLR7-antiviral vs. TLR2-immunopathological responses in COVID-19
R. M. van der Sluis, L. B. Cham, … M. R. Jakobsen·bioRxiv·Nov 23, 2021
- Plasmacytoid dendritic cells produce type I interferon and reduce viral replication in airway epithelial cells after SARS-CoV-2 infection
L. Cervantes-Barragan, A. Vanderheiden, … M. S. Suthar·bioRxiv·May 12, 2021
- Differential plasmacytoid dendritic cell phenotype and type I Interferon response in asymptomatic and severe COVID-19 infection
M. Severa, R. A. Diotti, … E. Coccia·bioRxiv·Apr 17, 2021
- The type 2 asthma mediator IL-13 inhibits SARS-CoV-2 infection of bronchial epithelium
L. R. Bonser, W. L. Eckalbar, … D. J. Erle·bioRxiv·Feb 25, 2021